Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was E£169 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was E£527 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's annualizedROC % for the quarter that ended in Mar. 2026 was 0.00%.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 40.56%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.00%.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's annualizedROC % for the quarter that ended in Mar. 2026 is calculated as:
Note:
The Operating Income data used here is four times the quarterly (Mar. 2026) data.
2. Joel Greenblatt's definition of Return on Capital:
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EBIT Related Terms
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EBIT Chart
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Annual Data
Trend
Jun24
Jun25
EBIT
369.40
234.16
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Quarterly Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EV-to-EBIT vs Drug Manufacturers Industry
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EBIT Calculation
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£527 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a EBIT of E£527 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EBIT too high?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current EBIT is E£527 Mil. Overall, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EBIT compare to ZTS and UTHR?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EBIT of E£527 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current EBIT is E£527 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile stock overvalued right now?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a current EBIT of E£527 Mil. The current EBIT is E£527 Mil. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's overall GF Score™ is 28/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH), the current EBIT is E£527 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Business Description
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile manufactures and markets pharmaceuticals, medicinal materials, chemical products and surgical threads and medical solutions.
28GF Score
Get the complete analysis for CAI:NIPH
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:NIPH has been successfully added to your 
